Special Issue

Genetics, Personalized Diagnosis and Treatment of Oral Disease

Message from the Guest Editors

We are proud to serve as for this Special Issue of JPM (ISSN: 2075-4426, IF 3.508) entitled "Advances and Perspectives in Diagnosis and Treatment Strategies for Prostate Cancer". Prostate cancer is the second most diagnosed cancer in men, constituting one of the leading causes affecting men's global health and quality of life. In recent years, a significant improvement in diagnostic techniques has occurred, allowing for the earlier detection of prostate cancer, due to the rise of magnetic resonance imaging (MRI) and the use of the PI-RADS™ v2 score. Moreover, based on histological reports, patient-tailored prostate cancer treatment strategies range from active surveillance, watchful waiting, or focal therapy to open-laparoscopic-robotic radical prostatectomy or radiotherapy. With this in mind, the aim of our Special Issue is to highlight the latest advances in the landscape of the diagnosis and treatment of prostate cancer. Considering the above, we would like to cordially involve you in this emerging research field. We would be pleased to know of your interest in contributing to our Special Issue.

Guest Editors

Dr. Yongchu Pan

Dr. Dong Han

Dr. Miao He

Deadline for manuscript submissions

closed (10 September 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/162945

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

